This inventor holds 1 USPTO granted patent. Top assignee: Aicuris Anti-Infective Cures Ag. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Innovator Kurt Vogtli: Advancements in Pharmaceutical Formulations
Introduction: Kurt Vogtli, an inventive force hailing from Oberhofen, Switzerland, has made significant contributions to the field of pharmaceutical science. With a focus on creating innovative compounds that enhance medication stability and effectiveness, Vogtli boasts one patent that showcases his expertise in this critical area of research.
Latest Patents: The primary patent attributed to Kurt Vogtli is for "Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate." This invention features a well-defined particle size distribution and specific surface area range. Its innovative attributes contribute to increased long-term stability and improved release kinetics from pharmaceutical compositions. Furthermore, this patent includes insights into the pharmacokinetic and pharmacodynamic in vivo profiles of the resultant free base upon administration of the crystalline compound.
Career Highlights: Currently, Kurt Vogtli is associated with Aicuris Anti-infective Cures AG, a company dedicated to advancing anti-infective treatments. Through his work, Vogtli has become a key player in research that aims to improve the delivery and effectiveness of pharmaceutical compounds aimed at combating infections.
Collaborations: In his professional journey, Kurt Vogtli has collaborated with notable colleagues such as Wilfried Schwab and Alexander Birkmann. Together, they work towards innovative solutions in the pharmaceutical industry, pushing the boundaries of what is possible in medicinal therapies.
Conclusion: Kurt Vogtli stands out as a pioneering inventor in the realm of pharmaceutical formulations. His patent on crystalline compounds not only impacts medication stability but also enhances therapeutic outcomes for patients. As he continues to collaborate and innovate within Aicuris Anti-infective Cures AG, Vogtli’s contributions will undoubtedly pave the way for further advancements in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile